#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	15662	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2079	746.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1454	1454	C	873	C	831	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28778	23S	2890	2890	99.83	23S.l6.c4.ctg.1	3625	791.2	0	.	n	.	0	T695C	SNP	695	695	T	1083	1083	C	888	C	835	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28778	23S	2890	2890	99.83	23S.l6.c4.ctg.1	3625	791.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1725	1725	A	1018	A,G	957,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28778	23S	2890	2890	99.83	23S.l6.c4.ctg.1	3625	791.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2359	2359	C	890	C,T	823,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28778	23S	2890	2890	99.83	23S.l6.c4.ctg.1	3625	791.2	0	.	n	.	0	C2172T	SNP	2172	2172	C	2560	2560	T	882	T,C	825,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28778	23S	2890	2890	99.83	23S.l6.c4.ctg.1	3625	791.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2985	2985	T	832	T	800	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28778	23S	2890	2890	99.83	23S.l6.c4.ctg.1	3625	791.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2433	2433	A	920	A,G	877,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1946	folP	852	852	100.0	folP.l15.c30.ctg.1	1485	129.8	1	SNP	p	R228S	1	.	.	682	684	AGC	922	924	AGC	193;197;195	A;G;C	189;192;191	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5180	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3267	157.8	1	SNP	p	S91F	0	.	.	271	273	TCC	538	540	TCC	191;189;189	T;C;C	182;180;179	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5180	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3267	157.8	1	SNP	p	D95G	0	.	.	283	285	GAC	550	552	GAC	180;180;182	G;A;C	171;168;173	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5180	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3267	157.8	1	SNP	p	D95N	0	.	.	283	285	GAC	550	552	GAC	180;180;182	G;A;C	171;168;173	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	1724	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1390	123.5	1	SNP	p	G45D	1	.	.	133	135	GAC	514	516	GAC	197;196;199	G;A;C	192;186;191	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	902	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1141	78.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5270	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3052	171.8	1	SNP	p	D86N	0	.	.	256	258	GAC	548	550	GAC	206;207;209	G,A;A;C	192,1;190;195	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5270	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3052	171.8	1	SNP	p	S87R	0	.	.	259	261	AGT	551	553	AGT	210;207;208	A;G;T	195;195;191	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5270	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3052	171.8	1	SNP	p	S87W	0	.	.	259	261	AGT	551	553	AGT	210;207;208	A;G;T	195;195;191	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5270	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3052	171.8	1	SNP	p	S87I	0	.	.	259	261	AGT	551	553	AGT	210;207;208	A;G;T	195;195;191	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5270	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3052	171.8	1	SNP	p	S88P	0	.	.	262	264	TCC	554	556	TCC	207;209;210	T;C;C	190;196;198	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4322	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2522	169.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1446	1448	GGC	219;217;215	G;G;C	207;203;199	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	A438V	NONSYN	1312	1314	GCA	1737	1739	GTC	230;231;233	G;T;C	217;216;220	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	V444E	NONSYN	1330	1332	GTT	1755	1757	GAA	234;235;236	G;A;A	223;220;222	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	L448V	NONSYN	1342	1344	CTC	1767	1769	GTC	238;238;238	G;T;C	228;223;224	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	Q458K	NONSYN	1372	1374	CAA	1797	1799	AAA	229;225;226	A;A;A	215;212;213	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	I462V	NONSYN	1384	1386	ATA	1809	1811	GTC	230;228;223	G;T;C	215;210;210	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	F463I	NONSYN	1387	1389	TTC	1812	1814	ATC	222;215;214	A;T;C	208;200;201	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	E465A	NONSYN	1393	1395	GAA	1818	1820	GCC	204;204;204	G;C;C,A	193;191;191,1	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	R469K	NONSYN	1405	1407	CGC	1830	1832	AAA	201;200;203	A;A;A	188;186;188	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	E470K	NONSYN	1408	1410	GAG	1833	1835	AAA	204;203;205	A;A;A	190;189;190	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	N473E	NONSYN	1417	1419	AAT	1842	1844	GAG	201;198;198	G;A;G	186;181;182	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	N513Y	NONSYN	1537	1539	AAC	1962	1964	TAC	205;207;210	T;A;C	197;193;198	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	G517A	NONSYN	1549	1551	GGT	1974	1976	GCC	228;230;230	G,T;C;C	216,1;212;217	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	A550T	NONSYN	1648	1650	GCA	2073	2075	ACA	168;170;173	A,G;C;A	146,1;153;156	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	P553V	NONSYN	1657	1659	CCC	2082	2084	GTC	183;184;188	G,C;T,C;C	158,1;148,1;162	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	K556Q	NONSYN	1666	1668	AAA	2091	2093	CAA	188;189;189	C,A;A;A	173,1;174;175	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	0	.	p	.	0	I557V	NONSYN	1669	1671	ATT	2094	2096	GTT	187;187;190	G,A;T;T	169,1;169;171	.	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1356	1358	GCA	221;223;226	G;C;A	206;212;216	penA.14.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1359	1361	ATC	230;227;228	A;T;C	221;215;217	penA.14.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1371	1373	GTG	221;222;218	G;T;G	208;207;207	penA.14.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1371	1373	GTG	221;222;218	G;T;G	208;207;207	penA.14.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1929	1931	GCG	172;170;170	G;C;G	153;146;150	penA.14.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1929	1931	GCG	172;170;170	G;C;G	153;146;150	penA.14.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2052	2054	GGT	198;197;198	G;G;T	183;183;180	penA.14.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2061	2063	GGC	184;184;183	G,A,C;G;C	160,1,1;159;164	penA.14.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	4082	penA	1749	1749	95.54	penA.l6.c4.ctg.1	2494	163.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2079	2081	CCG	177;179;181	C;C;G	155;158;157	penA.14.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6010	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3229	185.7	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1656	1658	CTG	184;184;183	C;T,C;G	166;168,1;170	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2348	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1916	122.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	650	650	C	162	C	150	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	G38E	NONSYN	112	114	GGA	371	373	GAA	224;221;222	G;A;A	211;209;209	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	R40Q	NONSYN	118	120	CGG	377	379	CAG	227;229;228	C;A,G;G	213;213,1;214	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	S46G	NONSYN	136	138	AGC	395	397	GGC	240;242;245	G;G;C	226;228;230	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	E48G	NONSYN	142	144	GAA	401	403	GGA	247;247;246	G;G,A;A	232;230,1;230	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	T87A	NONSYN	259	261	ACT	518	520	GCT	206;207;209	G;C;T	192;189;188	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	T89S	NONSYN	265	267	ACC	524	526	AGC	216;218;214	A;G;C	204;203;196	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	.	MULTIPLE	358	359	AA	616	617	CG	208;209	C;G,A	201;200,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	.	MULTIPLE	361	362	GA	619	621	CAG	211;209;205	C,G;A;G	203,1;202;199	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	N122K	NONSYN	364	366	AAC	623	625	AAA	204;204;202	A;A;A	198;199;195	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	K143E	NONSYN	427	429	AAA	686	688	GAA	225;223;224	G;A;A	215;212;211	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	V151A	NONSYN	451	453	GTA	710	712	GCA	222;222;220	G;C;A	208;208;202	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	818	820	CGA	240;240;240	C;G;A	225;227;227	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	A215T	NONSYN	643	645	GCT	902	904	ACT	242;242;245	A;C;T	234;232;236	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	905	907	CAT	245;247;247	C;A;T	234;235;236	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	I218M	NONSYN	652	654	ATA	911	913	ATG	250;252;255	A;T;GCCC,GCC	239;241;240,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1025	1027	GCA	231;229;229	G;C;A	222;220;220	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1028	1030	ACG	227;224;221	A;C;G	215;215;213	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	S258R	NONSYN	772	774	AGT	1031	1033	AGG	220;222;222	A;G;G	212;212;211	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1034	1036	GTT	224;224;227	G;T;T	215;211;217	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1094	1096	GTA	243;245;250	G;T;A	228;228;230	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1133	1135	ACT	269;267;266	A;C;T	249;249;248	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1139	1141	GAT	268;264;264	G;A,C;T	249;246,1;247	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	S295D	NONSYN	883	885	AGT	1142	1144	GAT	264;265;265	G;A;T	246;244;254	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1148	1150	AAC	270;265;264	A;A;C,A	257;253;248,2	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1151	1153	CAC	264;263;266	C;A;C	248;250;249	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	1	SNP	p	G120K	1	.	.	358	360	AAG	616	618	CGG	208;209;207	C;G,A;G,A	201;200,1;197,1	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	1	SNP	p	D121N	0	.	.	361	363	GAC	619	622	CGC	211;205;202	C,G;G;C	203,1;199;197	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2858	porB1b	1047	1047	96.47	porB1b.l15.c17.ctg.1	1451	195.5	1	SNP	p	A121D	1	.	.	361	363	GAC	619	622	CGC	211;205;202	C,G;G;C	203,1;199;197	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11436	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	4904	232.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1952	1954	AAT	236;236;236	A,C;A;T	227,1;226;225	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1278	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	993	126.3	1	SNP	p	V57M	1	.	.	169	171	ATG	480	482	ATG	280;277;276	A;T;G	261;260;257	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
